The firms have begun a validation sudy of the Down syndrome test, which runs on Illumina’s HiSeq platform.
Illumina will provide its DNA analysis technology, Barts will supply tissue samples, and Source BioScience will develop the test.
The company will investigate the use of PacBio's RS platform for use in the test protocol.
After verifying that organ transplant rejection corresponds to a rise in cell-free donor DNA in recipient blood samples, researchers from Stanford University developed a sequencing-based approach for assessing these donor DNA levels.
The startup will use its using next-generation sequencing-based technology for applications aimed at identifying biothreats.
The space is being housed at its headquarters and will run the company's planned Trisomy 21 test.
The molecular diagnostics firm currently has a patent application for a method of using DNA sequencing technology for identifying biomarkers of autoimmune disease.
Enzo plans to seek approval for and market MultiGen's antenatal infectious disease tests in New York and in other US regions.
NPR reports that many USDA researchers working at the two agencies that are relocating to the Kansas City area are declining to go.
Genetic genealogy has helped exonerate a man who has been jailed for 20 years, Agence France Presse reports.
A new report says genetically modified food might be necessary to be able to feed a planet of nearly 10 billion people, Bloomberg says.
In Nature this week: new RNA editing approach called LEAPER, draft assembly of Musa balbisiana banana genome, and more.